Revolution Medicines to Participate in March 2025 Investor Conferences REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in three upcoming investor conferences. Details of the company’s participation are as follows: TD Cowen 45th Annual Healthcare Conference Fireside Chat Date/Time: Monday, March 3 at 1:50...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will hos...
Texas Capital Recognized with Notable Industry Awards DALLAS, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, begins the year with notable awards from Bankrate, GOBankingRates and Newsweek recognizing its excellence in financial services. These accolades highlight the firm’s commitment to providing clients with top-tier financial products and solutions, strengthening the company’s position as the premier full-service financial services firm headquartered in Texas. Key Highlights Bankrate – Best Regional Bank (Two ...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET. To access the live webcast of the pr...
Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Preferred Stock DALLAS, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, and its board of directors declared a cash dividend of $14.375 per share of the 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”), equivalent to $0.359375 per depositary share, each representing a 1/40th interest in a share of the Series B Preferred Stock. The depositary shares are traded on the NASDAQ under the symbol “TCBIO.” The...
Texas Capital Bancshares, Inc. Announces Fourth Quarter and Full Year 2024 Results Income in fee areas of focus(1) increased 38% year-over-year Strong balance sheet growth with total deposits increasing 13% and total loans growing 10% year-over-year Book Value and Tangible Book Value(2) per share both increased 8% year-over-year, reaching record levels Capital ratios continue to be strong, including 11.4% CET1 and 15.4% Total Capital DALLAS, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, announced operating re...
Texas Capital Elevates President & Chief Executive Officer Rob C. Holmes to Additional Responsibilities as Chairman of the Board-Elect in Recognition of Transformation Progress DALLAS, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced that its Board of Directors (the Board) unanimously elected Rob C. Holmes, Texas Capital’s President & Chief Executive Officer and existing Board Director, to also serve as Chairman of the Board immediately following the 2025 Annual Meeting of Stockholders. “The decision to ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.